Immune Design Reports Third Quarter 2018 Financial Results and Provides Corporate Update

On November 6, 2018 Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, reported financial results and a corporate update for the third quarter ended September 30, 2018 (Press release, Immune Design, NOV 6, 2018, View Source [SID1234530878]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Given the promising data to date with G100, our intratumoral TLR4 cancer therapy, we are aggressively advancing an expanded clinical development plan for this proprietary agent," said Carlos Paya, M.D., Ph.D., President and Chief Executive Officer of Immune Design. "While preserving the option to develop our other approaches in the future, we believe that G100’s unique mechanism of action in B cell malignancies warrants our near-term focus. Its single agent and combination activity coupled with a preferable safety profile are differentiating features that we believe better position us for clinical success. We look forward to sharing data as they mature later this year and over the next 12-18 months."

Corporate Highlights


In October, the company announced prioritization of resources to support expanded clinical development of G100.

Initial focus will be in combination with pembrolizumab in relapsed follicular lymphoma (FL) patients who have received three prior lines of systemic therapy.

Pursuant to discussions with the FDA, these patients may represent an unmet medical need, which may allow for a single arm study and potential for accelerated approval path.

In an open label setting scheduled to begin in the first quarter of 2019, the plan is to evaluate:

clinical activity based on Objective Response Rate (ORR) and Duration of Response; and

patients by "TLR4HIGH" expression, an emerging biomarker that may provide the opportunity to pre-select patients with a higher likelihood to respond to G100.

In addition, the company:

plans to evaluate G100 in earlier lines of lymphoma in combination with rituximab; and

is evaluating the potential development of G100 in other indolent lymphomas, as well as aggressive lymphomas and solid tumors.


Upcoming Data Presentations

As announced earlier today, G100 will be featured in three presentations at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) meeting, November 9 and 10.

"Higher dose single-agent intratumoral G100 (a TLR4 agonist) results in increased biomarker activity and improved clinical outcomes in patients with follicular lymphoma"

A new cohort of 18 follicular lymphoma patients who received 20ug of G100 with low-dose radiation showed increased biomarker activity and improved clinical outcomes in comparison to the 10ug dose (n=16), without the use of an anti-PD-1 antibody.


Patients receiving the 20ug dose showed a positive trend of more rapid and deeper abscopal responses than those receiving 10ug.

Patients receiving 20ug showed improved responses in the TLR4HIGH subpopulation:

Patients receiving 20ug had a 60% ORR (6/10) as compared to 29% ORR (2/7).

Approximately 60% of the patients in both groups tested positive for baseline
TLR4HIGH >50% TLR4 expression prior to G100 treatment.

"Synergistic anti-tumor effects of TLR4 agonist G100 and anti-OX40 antibody"

"The TLR4 agonist G100 enhances the efficacy of adoptive T-cell therapy"

G100 will also be featured at the upcoming American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting on December 2, 6-8 pm, in a presentation titled: "Long Term Follow-up of a Phase 2 Study Examining Intratumoral G100 Alone and in Combination with Pembrolizumab in Patients with Follicular Lymphoma."

Follow up of the patient data presented at ASH (Free ASH Whitepaper) 2017 (n=26) from a randomized study comparing G100 with low-dose radiation +/- Keytruda (pembrolizumab).

Responses are durable with a trend towards longer progression free survival (PFS) on the arm with pembrolizumab (11.1 months) vs. the arm without (7.4 months).


Together, Immune Design believes these new clinical and preclinical data:

Support using the higher, 20ug dose of G100 in further development;

Provide additional evidence of G100’s clinical activity; and

Support the further development of G100 as a single agent and in combination with other therapies, initially in B cell malignancies.

Financial Results

Third Quarter


Immune Design ended the third quarter of 2018 with $107.5 million in cash and cash equivalents, short-term investments, and other receivables compared to $144.2 million as of December 31, 2017.

Net loss and net loss per share for the third quarter of 2018 were $14.0 million and $0.29, respectively, compared to $13.4 million and $0.52, respectively, for the third quarter of 2017.

Revenue did not materially differ over the comparative periods. Revenue for the third quarter of 2018 was $0.5 million and was primarily attributable to $0.2 million in collaboration revenue associated with the Sanofi G103 HSV2 vaccine collaboration and $0.2 million in product sales to collaboration partners and other third parties. Revenue for the third quarter of 2017 was $0.5 million and was primarily attributable to collaboration revenue associated with the Sanofi G103 collaboration.

Research and development expenses for the third quarter of 2018 were $11.2 million, compared to $10.2 million for the same period in 2017. The $1.0 million increase was primarily attributable to milestone payments of $1.7 million due to third parties as a result of the commencement of our SYNOVATE study, which was offset by a decrease in contract manufacturing services and personnel-related expenses.

General and administrative expenses did not materially differ over the comparative periods. For the three months ended September 30, 2018, general and administrative expenses were $3.8 million compared to $3.9 million for the same period in 2017.

Year-to-Date


Net cash used in operations for the nine months ended September 30, 2018 was $40.3 million.


Net loss and net loss per share for the nine months ended September 30, 2018 were $41.2 million and $0.85, respectively, compared to $39.9 million and $1.56, respectively, for the same period in 2017.

Revenue for the nine months ended September 30, 2018 was $1.7 million and was primarily due to $1.1 million in collaboration revenue associated with the Sanofi G103 collaboration and $0.6 million in product sales to our collaboration partners and other third parties. Revenue for the nine months ended September 30, 2017 was $6.7 million and was primarily attributable to $6.4 million in collaboration revenue associated with the Sanofi G103 collaboration and $0.3 million in product sales to collaboration partners other third parties.

Research and development expenses for the nine months ended September 30, 2018 were $32.5 million compared to $35.1 million for the same period in 2017. The $2.6 million decrease was primarily due to a decrease of $4.9 million in contract manufacturing costs and a slight decrease of $0.3 million in clinical trial costs. This decrease was offset by an increase of $0.9 million in personnel-related expenses and $1.7 million of milestone payments.

General and administrative expenses did not materially differ over the comparative periods. For the nine months ended September 30, 2018, general and administrative expenses were $11.8 million compared to $11.9 million for the same period in 2017.

Cash Guidance

Based on current expectations, Immune Design expects to have cash to fund operations into 2021.

Conference Call Information

Immune Design will host a conference call and live audio webcast this afternoon at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss third quarter 2018 financial results and provide a corporate update.

The live call may be accessed by dialing 844-266-9538 for domestic callers and 216-562-0391 for international callers. A live webcast of the call will be available online from the investor relations section of the Immune Design website at View Source and will be archived there for 30 days. A telephone replay of the call will be available for five days by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference code 1359112.

BerGenBio reports ~80% improvement in PFS of AXL-positive vs AXL-negative NSCLC patients in bemcentinib + KEYTRUDA PhII combination trial

On November 6, 2018 BerGenBio ASA (OSE:BGBIO) reported that a Late-breaking Abstract detailing median progression-free-survival (mPFS) during the first stage of its phase II clinical trial with bemcentinib, a first-in-class selective oral AXL inhibitor, in combination with the anti-PD-1 therapy KEYTRUDA (pembrolizumab) in patients with previously treated, advanced non-small cell lung cancer (NSCLC) has been published today and will be presented at the annual Society for Immunotherapy in Cancer (SITC) (Free SITC Whitepaper) 2018 congress in Washington D.C. (7-10 November 2018) (Press release, BerGenBio, NOV 6, 2018, View Source [SID1234530877]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

24 patients have been enrolled during the first stage of the combination trial. The median time that patients lived without progression of their disease (mPFS) was 5.9 months in AXL positive patients (n=10) and thus greater than the mPFS of 3.3 months in patients whose tumours did not show any AXL expression as per BerGenBio’s proprietary biomarker test (n=11). mPFS is an outcome criterion that measures the time that patients can stay on treatment in the trial without their disease getting worse.

The full abstract is available at View Source and a poster will be presented by the study’s lead investigator at the SITC (Free SITC Whitepaper) congress in Washington DC on Friday, 9 November 2018.

Richard Godfrey, Chief Executive Officer of BerGenBio, commented: "In addition to very encouraging tumour response data previously reported, today we can reveal for the first time the median progression-free survival (mPFS) for patients on our phase II trial combining bemcentinib with KEYTRUDA. We are excited to report in the late-breaking abstract that patients with AXL-positive disease showed an almost 80 percent improvement in mPFS compared to AXL-negative patients. Whilst the number of patients included in stage 1 of the trial remains relatively small, we are very encouraged that mPFS of almost six months in AXL-positive patients on the bemcentinib/KEYTRUDA combination trial compares favourably to historically reported PFS data from advanced NSCLC patients on anti-PD-1 therapy, such as KEYTRUDA, alone (1, 2). Of note, PFS during stage 1 of our trial was not driven by high PD-L1 expression as the population studied was predominantly negative or only weakly positive for the PD-L1 biomarker. This indicates that we would only expect a limited benefit from KEYTRUDA monotherapy. Stage 2 of the trial is actively recruiting and we look forward to further update outcome data at future medical conferences."

Study Design and additional data from the Late-breaking Abstract
A Phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Analysis of the first stage (BerGenBio study reference: BGBC008)

Matthew Krebs, PhD, et al
Category: 33rd Annual Meeting Late-Breaking Abstracts Presentation number: P715
Friday 9 November, 12:45 – 2:15 p.m Eastern time, Hall E
The BGBC008 study is investigating whether adding bemcentinib to KEYTRUDA (pembrolizumab) in previously treated, PD-L1 unselected and immunotherapy naive patients with advanced adenocarcinoma of the lung is well tolerated and improves patient outcomes. A total of 48 patients across two stages will be enrolled.

The first stage is fully enrolled with 24 patients, of which 5 patients remain on treatment or in follow-up; the second stage is open and enrolling
The biomarker analysis revealed that
10 of 21 evaluable patients were AXL positive (48%)
Of 21 patients evaluated for PD-L1 expression, 11 (46%) were PD-L1 negative (< 1%); 7 (29%) were weakly positive (1-49%) and 2 (8%) were strongly positive ( >50%)
40% overall response rate (ORR) was reported in AXL-positive patients with a disease control rate (DCR) of 70%, compared with 9% ORR (45% DCR) for AXL-negative patients
Median progression-free survival was 5.9 months in AXL-positive patients, compared to 3.3 months in AXL-negative patients

An update from BerGenBio’s biomarker and companion diagnostic programme will also be presented as a poster within the regular abstract section at SITC (Free SITC Whitepaper) on Nov 9th. Both presentations will be made available on the BerGenBio website in the Investors / Presentations section on the day of presentation.

END

About SITC (Free SITC Whitepaper)
The Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) is the world’s leading member-driven organisation specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Over 4,000 delegates are expected to attend the SITC (Free SITC Whitepaper) 33rd Annual Congress in Washington D.C. on Nov 7-10 2018. For more information, please see www.sitcancer.org

Late-breaking abstracts highlight novel and potentially practice-changing studies, and their acceptance for presentation is subject to favourable assessment by a panel of clinical and scientific experts. In total, only 21 abstracts were accepted in the late-breaking category at this year’s SITC (Free SITC Whitepaper) congress: View Source

About the BGBC008 trial
A Phase II study of bemcentinib in combination with pembrolizumab in patients with previously treated advanced NSCLC.

The BGBC008 trial is a phase II multi-centre open-label study of bemcentinib in combination with KEYTRUDA (pembrolizumab) in previously treated, immunotherapy naive, patients with advanced adenocarcinoma of the lung, the most common form of non-small cell lung cancer (NSCLC). The objective of the trial is to determine the anti-tumour activity of this novel drug combination. Responses will be correlated with biomarker status (including AXL kinase and PD-L1 expression).

For more information please access trial NCT03184571 at www.clinicaltrials.gov.

About AXL
AXL kinase is a cell membrane receptor and an essential mediator of the biological mechanisms that drive aggressive and life-threatening diseases. In cancer, AXL drives tumour survival, treatment resistance and spread, as well as suppressing the body’s immune response to tumours. AXL expression has been established as a negative prognostic factor in many cancers. AXL inhibitors, therefore, have potential value at the centre of cancer combination therapy, addressing significant unmet medical needs and multiple high-value market opportunities.

ATHERSYS REPORTS THIRD QUARTER 2018 RESULTS

On November 6, 2018 Athersys, Inc. (NASDAQ: ATHX) reported its financial results for the period ended September 30, 2018 (Press release, Athersys, NOV 6, 2018, View Source [SID1234530876]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Highlights of the third quarter of 2018 and recent events include:

Completed enrollment of our Phase 1/2 study evaluating MultiStem therapy in acute respiratory distress syndrome (ARDS) patients;

Commenced enrollment of patients in the MASTERS-2 Phase 3 registration study for ischemic stroke;

Continued to support Healios’ ongoing TREASURE study for ischemic stroke in Japan by providing clinical product;

Extended to December 6, 2018, Healios’ option and negotiation period for further expansion of the collaboration, including an exclusive option for a license to develop and commercialize MultiStem therapy in China for certain indications;

Recognized revenues of $2.3 million for the quarter ended September 30, 2018 and net loss of $9.7 million, or $0.07 net loss per share, for the quarter ended September 30, 2018; and

Cash and cash equivalents were $48.0 million at the end of the third quarter.

"We had another solid quarter in the third quarter of 2018 as we advanced key initiatives, reflected by the completion of enrollment in our exploratory clinical trial evaluating administration of MultiStem to patients suffering from ARDS and the initiation of enrollment in the Phase 3 MASTERS-2 study for treating ischemic stroke," commented Dr. Gil Van Bokkelen, Chairman & CEO at Athersys. "We are working collaboratively with Healios in multiple areas, and we further strengthened our core capabilities.

"In addition, we have maintained a solid balance sheet as we continue to implement our strategic plan, working toward the achievement of our key goals on behalf of our shareholders and the patients we are committed to help," concluded Dr. Van Bokkelen.

Third Quarter Results

Revenues increased to $2.3 million for the three months ended September 30, 2018 compared to $0.4 million for the three months ended September 30, 2017. Our revenues are generally derived from license fees, manufacturing-related activities for Healios, royalty and related contract revenue from our collaborations, and grant revenue.

Research and development expenses increased to $9.5 million for the three months ended September 30, 2018 from $5.4 million for the comparable period in 2017. The $4.1 million increase is primarily associated with increased clinical development costs of $3.0 million, increased personnel costs of $0.6 million, increased license fees of $0.2 million and increased internal research supplies and other of $0.3 million. The $3.0 million increase in our clinical costs during the period is primarily a result of increased clinical product manufacturing costs, covered in part by Healios, technology transfer services associated with planned Japan manufacturing for Healios, process development activities to support large-scale manufacturing, and costs related to our MASTERS-2 clinical trial that began enrolling patients in the third quarter of 2018.

General and administrative expenses increased to $2.6 million for the three months ended September 30, 2018 from $2.1 million in the comparable period in 2017. The $0.5 million increase was due primarily to increases in professional fees, consulting services, personnel costs and other administrative costs compared to the same period last year.

Net loss for the third quarter was $9.7 million in 2018 compared to a net loss of $7.2 million in 2017. The difference of $2.5 million reflects the above variances, as well as an increase of $0.2 million in other income.

In the nine months ended September 30, 2018, net cash used in operating activities was $8.8 million compared to $17.9 million in the nine months ended September 30, 2017. The difference reflects in part $15.0 million in license fees paid by Healios in connection with the collaboration expansion and an increase in clinical development activity in 2018. Healios is obligated to make two more license fee payments of $2.5 million each in December 2018 and March 2019. At September 30, 2018, we had $48.0 million in cash and cash equivalents, compared to $29.3 million at December 31, 2017.

Conference Call

William (B.J.) Lehmann, President and Chief Operating Officer, and Laura Campbell, Senior Vice President of Finance, will host a conference call today to review the results as follows:

Date Tuesday, November 6th, 2018
Time 4:30 p.m. (Eastern Time)
Telephone access: U.S. and Canada 800-273-1254
Telephone access: International 973-638-3440
Access code 7396506
Live webcast

www.athersys.com, under the Investors section
A replay will be available for on-demand listening shortly after the completion of the call until 11:59 PM Eastern Time on November 20, 2018 at the aforementioned URL, or by dialing (800) 585-8367 or (855) 859-2056 in the U.S. and Canada, or from abroad (404) 537-3406, and entering access code 7396506.

Aduro to Host and Webcast an Investor Event to Review Data Presented at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting

On November 6, 2018 Aduro Biotech, Inc. (NASDAQ: ADRO) reported that the company will host and webcast an investor event on Friday, November 9, 2018 at 6:30 p.m. Eastern Time in Washington, D.C (Press release, Aduro Biotech, NOV 6, 2018, View Source;p=RssLanding&cat=news&id=2375696 [SID1234530875]). The event will feature special guest speaker Jason J. Luke, M.D., FACP, Assistant Professor of Medicine at the University of Chicago and a principal investigator for the Phase 1 dose-finding studies of ADU-S100 (MIW815), a novel STING (stimulator of interferon genes) pathway activator. ADU-S100 is currently being evaluated as a single agent and in combination with spartalizumab (PDR001), an investigational anti-PD-1 compound in patients with advanced/metastatic solid tumors or lymphomas.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live webcast and subsequent archived recording of this and other company presentations, please visit the investor section of Aduro’s website at www.aduro.com. The archived webcast will remain available for replay on Aduro’s website for 30 days.

Aduro’s posters will be on display on Friday, November 9, 2018 from 8 a.m. – 8 p.m. ET and Saturday, November 10, 2018 from 8 a.m. – 8:30 p.m. ET in Hall E. at the Walter E. Washington Convention Center. Details of Aduro’s posters and oral presentations are as follows:

P309 Phase I dose-finding study of MIW815 (ADU-S100), an intratumoral
STING agonist, in patients with advanced solid tumors or lymphomas
Session: Rapid Oral Abstract Presentation Session
Date: Saturday, November 10, 2018, 1:00 p.m. ET
Location: Room 204ABC, Walter E. Washington Convention Center

P351 ADU-S100 (MIW815) Synergizes with Checkpoint Inhibition to Elicit an
Anti-Tumor CD8+ T Cell Response to Control Distal Tumors

P516 SIRPα blockade increases the activity of multiple myeloid lineage cells,
enhances dendritic cell cross-presentation, and aids in remodeling the
tumor microenvironment
Session: Concurrent Session 104: Immune Checkpoints – Beyond PD-1
Date/Time: Friday, November 9, 2018, 4:30 p.m. ET
Location: Hall D, Walter E. Washington Convention Center

P517 Pan-allele anti-SIRPα antibodies that block the SIRPα–CD47 innate
immune checkpoint

MEI Pharma To Present at Stifel 2018 Healthcare Conference

On November 6, 2018 MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, reported that Daniel P. Gold, Ph.D., the Company’s president and chief executive officer, will present a corporate update at the Stifel 2018 Healthcare Conference on November 13, 2018 at 9:30 a.m. ET. The conference will take place November 13-14, in New York, N.Y (Press release, MEI Pharma, NOV 6, 2018, View Source [SID1234530873]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the event can be accessed on the Events & Presentations page of the Investors section of MEI Pharma’s website at View Source

An archived replay of the webcast will be available on MEI Pharma’s website for at least 30 days after the live event concludes.